[Form 4] Capitol Federal Financial, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Renovaro Inc. (NASDAQ: RENB) has called a virtual Special Meeting for 9:00 a.m. ET on 15 Aug 2025. Only shareholders of record on 15 Jul 2025 may vote.

Two proposals will be considered: (1) Reverse Stock Split—an amendment authorising the Board, at its discretion, to combine shares at any ratio between 1-for-3 and 1-for-10; (2) Adjournment—to solicit more proxies if needed. The split would cut the current 230.9 m outstanding shares to between 76.98 m and 23.09 m while keeping authorised shares at 350 m, effectively expanding the pool of unissued stock. Fractional shares will be rounded up to the next whole share; cash in lieu only applies to registered holders receiving fractions after rounding.

Rationale: RENB closed at $0.28 on 15 Jul 2025 and has received Nasdaq deficiency notices for (i) the $1.00 minimum bid and (ii) late annual meeting. Management believes a reverse split is the quickest path to restore compliance and broaden institutional ownership, though it warns the action cannot guarantee sustained price improvement and may reduce liquidity. A majority of votes cast is required; brokers may vote at their discretion because the item is classified as routine. The Board may abandon the split at any time before filing with Delaware.

Positive

• Averts Nasdaq delisting risk by targeting the $1.00 bid-price deficiency deadline of 13 Oct 2025.
• Fractional shares rounded up, eliminating cash-out friction for most holders.
• Flexible 1:3–1:10 range lets the Board tailor the split to prevailing market conditions.
• No filing fee required, keeping direct transaction costs minimal.

Negative

• Authorised share count unchanged, creating up to 327 m additional issuable shares and possible future dilution.
• Liquidity could fall with fewer shares outstanding, potentially widening bid–ask spreads.
• Price boost not guaranteed; shares may slip below $1.00 again, risking repeat non-compliance.
• Effective increase in board discretion over capital structure without further shareholder approval.

Insights

Equity Analyst

TL;DR: Reverse split aims to avert Nasdaq delisting, lift share price, and unlock broader investor base—moderately positive for current holders.

The company is trading at $0.28 versus the $1.00 minimum. Compressing shares 1:3–1:10 should mechanically boost the price to $0.90–$3.00, giving RENB until 13 Oct 2025 to regain compliance. Maintaining the 350 m authorised shares also supplies fresh capacity for future capital raises—helpful for a pre-revenue biotech. Because fractional shares are rounded up, dilution from the split itself is negligible. Historical data show that listings often stabilise after splits when combined with operating catalysts; however, RENB has yet to present one. Overall, the event removes a near-term existential risk and could marginally improve liquidity by attracting institutions barred from sub-$1 stocks.

Risk & Governance Specialist

TL;DR: Share count falls but authorised shares unchanged—potential dilution, weaker liquidity and no guarantee of bid-price compliance.

While a split satisfies Nasdaq optics, it does not address underlying fundamentals. By leaving the 350 m share authorisation intact, management dramatically enlarges the unused share pool (to as many as 326.9 m post-split). That capacity can be tapped for equity financings, stock plans or M&A, diluting existing holders. Liquidity risk rises: with as few as 23 m shares outstanding, daily volume may contract, widening spreads. If the price drifts back below $1.00, the company could face a second deficiency and limited remedial options. Governance watchers should monitor subsequent issuances and whether the Board uses the adjournment authority to pressure voter turnout.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

DICUS JOHN B

(Last) (First) (Middle)

C/O CAPITOL FEDERAL FINANCIAL, INC.

700 SOUTH KANSAS AVENUE

(Street)

TOPEKA KS 66603

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Capitol Federal Financial, Inc. [ CFFN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
CFFN common stock	07/28/2025		W	V	414,443(1)	A	$0	414,443	I	Trust 4(2)
CFFN common stock	07/28/2025		W	V	233,464(3)	A	$0	233,464	I	Trust 5(4)
CFFN common stock	07/28/2025		W	V	817,451(5)	D	$0	0	I	Trust 2(6)
CFFN common stock	07/28/2025		W	V	11,437(7)	D	$0	0	I	Trust 1(8)
CFFN common stock	07/28/2025		W	V	466,928(9)	D	$0	0	I	Trust 3(10)
CFFN common stock								1,333,352	D
CFFN common stock								91,421	I	ESOP

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
CFFN Phantom Stock 2022	$8.65							12/31/2025	12/31/2025	CFFN common stock	17,341(11)		17,341	D
CFFN Phantom Stock 2024	$5.91							12/31/2027	12/31/2027	CFFN common stock	13,830(11)		13,830	D
CFFN Non-qualified Stock Option	$11.91							(12)	05/14/2027	CFFN common stock	100,116		100,116	D

Explanation of Responses:

1. Transaction reflects receipt by John B. Dicus GST Nonexempt Trust dated June 19, 2024 of distribution of 408,725 shares from John C. Dicus Marital Trust GST Nonexempt and 5,718 shares from John C. Dicus Marital Trust GST Exempt.

2. John B. Dicus GST Nonexempt Trust dated June 19, 2024.

3. Transaction reflects receipt by John B. Dicus Irrevocable Trust GST dated 12/12/2012 of distribution of 233,464 shares from John C. Dicus Family Trust.

4. John B. Dicus Irrevocable Trust GST dated 12/12/2012.

5. Transaction reflects distribution of shares by John C. Dicus Marital Trust GST Nonexempt to beneficiaries.

6. John C. Dicus Marital Trust GST Nonexempt.

7. Transaction reflects distribution of shares by John C. Dicus Marital Trust GST Exempt to beneficiaries.

8. John C. Dicus Marital Trust GST Exempt.

9. Transaction reflects distribution of shares by John C. Dicus Family Trust to beneficiaries.

10. John C. Dicus Family Trust.

11. The phantom stock units were acquired under the Issuer's Deferred Incentive Bonus Plan and are settled in cash three years from the date of acquisition.

12. All options are vested.

Remarks:

	/s/ Kent G. Townsend, under Power of Attorney	07/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

When is Renovaro's (RENB) Special Meeting and how do I attend?

The virtual meeting is on 15 Aug 2025 at 9:00 a.m. ET. Visit http://www.virtualshareholdermeeting.com/RENB2025SM and enter your 16-digit control number.

What reverse split ratios are being proposed for RENB?

Shareholders will vote on a Board-selected ratio between 1-for-3 and 1-for-10.

Why does Renovaro want a reverse stock split?

To regain compliance with Nasdaq’s $1.00 minimum bid price after closing at $0.28 and to avoid possible delisting.

Will the number of authorised RENB shares change?

No. Authorised common stock remains 350 m, increasing the pool of unissued shares post-split.

How are fractional shares handled in the RENB split?

Fractions will be rounded up to the next whole share; registered holders will not receive cash unless a fraction remains after rounding.

What vote is needed to pass the reverse split proposal?

A majority of votes cast; brokers may vote discretionary as the matter is considered routine.